Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results
As compared to prior year Q2 IDEFIRIX product sales increased 76%.
LUND, Sweden, July 17, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced its interim report for January-June 2025.
Renée Aguiar-Lucander, CEO, Hansa Biopharma said, "In Q2 2025, the Company successfully secured additional financing and restructured its existing debt agreement with NovaQuest, ensuring the ability to report out data on two key Phase 3 programs in kidney transplantation and anti-GBM. With a cash runway now extending into Q2 2026, we can focus on near term catalysts, strategic pipeline decisions and driving the continued commercialization of IDEFIRIX in Europe."
Financial Performance
In Q2 2025, Hansa completed a successful capital raise with the support of new and existing shareholders. The funding will support two Phase 3 trial readouts in the second half of 2025 including the ConfIdeS US pivotal trial in kidney transplantation and GOOD-IDES-02 trial in anti-GBM.
As part of a directed share issue, Hansa and NovaQuest entered into an amended debt agreement in which the Company offset US $14.9M of outstanding debt through the issue of new shares (equity). The remaining debt will be paid in fixed cash payments in June 2027, June 2028 and June 2029. In addition, a true-up payment of approximately US $14.9M is due on January 31, 2026, which may be settled in cash or equity at the Company's discretion.
IDEFIRIX Q2 product revenues increased by 76% as compared to the same period last year. In Q2 2025, the Company delivered 47.8 MSEK in IDEFIRIX sales reflecting an increase of 76% as compared to previous year (27.2 MSEK) for the same time period. For the 1H 2025, IDEFIRIX sales amounted to 113.5 MSEK representing a 52% increase in product sales over 1H 2024, which represents approximately 80% of full year product sales for 2024.
Pipeline Progress
The Company remains on track to report data from the 20-HMedIdeS-17 study (ConfIdeS). A Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected in second half 2025, following data readout.
Positive data from the 15-HMedIdeS-09 Phase 2 trial including an indirect treatment comparison to the International Guillain-Barré Syndrome Outcome Study (IGOS) was presented at the Peripheral Nerve Society (PNS) annual meeting in May.
Enrolment is ongoing in GNT-018-IDES, a Phase 2 trial in Crigler Najjar to evaluate the efficacy and safety of Genethon's gene therapy, GNT-0003 following pre-treatment with imlifidase. The Phase 1b trial SRP-9001-104 with Sarepta remains on track for an initial data readout later this year.
Financial SummaryMSEK, unless otherwise stated – unaudited
Q2 2025
Q2 2024
1H 2025
1H 2024Revenue
49.1
34.3
115.5
90.3- thereof: Product sales1
47.8
27.2
113.5
74.7SG&A expenses
(90.5)
(88.2)
(166.5)
(179.5)R&D expenses
(95.8)
(91.7)
(160.1)
(194.6)Loss from operations
(154.8)
(187.4)
(248.2)
(346.8)Loss for the period
(178.9)
(207.9)
(216.0)
(426.5)Net cash used in operations
(111.7)
(189.2)
(263.6)
(378.3)Cash and short-term investments
354.4
705.0
354.4
705.0EPS before and after dilution (SEK)
(2.53)
(3.30)
(3.13)
(7.38)Number of outstanding shares
84,763,222
67,814,241
84,763,222
67,814,241Weighted average number of shares before and after dilution
70,802,763
62,929,675
68,937,930
57,800,736No of employees at the end of the period
140
146
140
1461 Product sales in the second quarter 2024 totaled 47.1 MSEK. Sales were offset by a provision totaling 19.9 MSEK for potentialcredits associated with volume discounts and potential refunds. First half 2024 product sales totaled 94.6 MSEK and were offset bythe provision totaling 19.9 MSEK. Net of the provision, first half product sales totaled 74.7 MSEK.
Conference Call Details
Hansa Biopharma will host a telephone conference today Thursday, 17 July 2025, at 14:00 CEST / 8:00 am EDT.
The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Hitto Kaufmann, CSTO, and Maria Törnsén COO and President U.S. The call will include a review of the interim results and a business and pipeline update. It will be held in English.
Slides used in the presentation will be live on the company website during the call under Events & Presentations and will also be made available online after the call.
To participate in the telephone conference, please use the dial-in details provided below:Participant Dial In (Toll Free): 1-833-821-3542Participant International Dial In: 1-412-652-1248*Please ask to be joined into the Hansa Biopharma call
Join the webcast here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=hUSedAeI
Contacts for more information:Evan Ballantyne, Chief Financial OfficerIR@hansabiopharma.com
About Hansa Biopharma
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results,c4208006
The following files are available for download:
https://mb.cision.com/Main/1219/4208006/3583230.pdf
20250717_HNSA_Q22025_QuarterlyReport_ENG
View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-reports-second-quarter-and-interim-january-june-2025-financial-results-302507683.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Tecan issues CHF 150 million straight bond
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Männedorf, Switzerland, August 14, 2025 – Today, the Tecan Group (SIX Swiss Exchange: TECN) successfully raised CHF 150 million through the issuance of a fixed rate domestic straight bond. The bonds will be issued at 100.195%, with a coupon of 0.850% and a duration of 5 years (final maturity September 11, 2030). Settlement date of the bonds is September 11, 2025. The bonds will be listed and begin trading on the SIX Swiss Exchange on September 9, 2025 (ISIN CH1474857070). The net proceeds of the issue will be used for general corporate purposes, including the repayment of the outstanding CHF 250 million bond maturing in October 2025. The bonds were placed with institutional investors and private banks in Switzerland under the joint lead management of UBS Investment Bank and Zürcher Kantonalbank, with Bank J. Safra Sarasin acting as the Co-Lead Manager. About TecanTecan ( improves people's lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2024, Tecan generated sales of CHF 934 million (USD 1,062 million; EUR 984 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191). For further information: Tecan GroupMartin BrändleSenior Vice President, Corporate Communications & IRTel. +41 (0) 44 922 84 30Fax +41 (0) 44 922 88 89investor@ DisclaimerThis press release and the information contained herein may not be published, distributed or transmitted to the United States (USA) Canada, Australia or Japan or any other jurisdiction into which the same would be unlawful, or given or transmitted to US persons (including legal entities) or to media with a general circulation in the USA. This bond will not be publicly offered for sale outside Switzerland. This media release does not constitute an offer to buy or subscribe for securities; it is neither an issue prospectus within the meaning of Article 35 FinSA nor a listing prospectus within the meaning of the SIX Swiss Exchange Listing Rules. Attachment Press ReleaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
TechCrunch
30 minutes ago
- TechCrunch
Lovable projects $1B in ARR within next 12 months
In Brief Vibe coding startup Lovable aims to hit $1 billion in annual recurring revenue within the next 12 months, according to its CEO, Anton Osika. Speaking on Bloomberg TV on Thursday, Osika said the company grows by at least $8 million in ARR each month. In a blog post written this summer, the company said it passed $100 million in ARR just eight months after making its first $1 million. Osika told Bloomberg Thursday the company is projecting to reach $250 million in ARR by the end of this year, and it hopes to reach $1 billion within the next 12 months. Founded in 2023, the company has become one of Europe's AI darlings. It hit a $1.8 billion valuation this summer, raising a $200 million Series A. This article was updated to reflect the spelling of the company's name.
New York Times
31 minutes ago
- New York Times
Tariffs Set to Hit Ireland, Where U.S. Drugmakers Play Tax Games
President Trump's planned 15 percent tariff on medicines from Europe has shined a spotlight on Ireland, which sends the United States tens of billions of dollars' worth of cancer medications, weight-loss drug ingredients and other pharmaceutical products each year. No other country sends more. Manufacturing blockbuster medications there offers tax benefits for American drug companies. But the appeal of Ireland for the industry goes deeper: Drugmakers have long shifted their patents and profits there, as well, to avoid billions of dollars in taxes. Such strategies can be legal but have been repeatedly challenged by tax authorities. For decades, the free flow of medicines across borders 'had the side effect of more or less providing manufacturers free rein to play tax games,' said Brad Setser, an economist at the Council on Foreign Relations. The tariffs on medicines from Europe, which could go into effect within weeks, create a new calculus for drugmakers. If they keep production in Ireland, they face billions of dollars in levies. If they move manufacturing to the United States, they will most likely face a range of increased costs. Drug companies could devise creative ways to limit the damage. They will be better positioned to weather the tariffs if they have 'sophisticated tax skills,' Wall Street analysts at the investment bank Leerink wrote to investors in July. Most executives and other employees of multinational drug companies are in the United States. So are a majority of their laboratories, clinical trial sites and, crucially, sales. But many of these companies register only a tiny share of the profits in the United States, helping them lower their overall tax bill. Forest Laboratories, now owned by AbbVie, shifted profits to Ireland for the antidepressant Lexapro, Gilead Sciences with its hepatitis C treatment Sovaldi and Regeneron with the eye drug Eylea. In the past three years, some of the largest drugmakers booked 91 percent of their profits overseas, on average, up from 76 percent in the mid-2010s, according to an analysis by Martin Sullivan, a tax economist who writes for the trade publication Tax Notes. Technically, drugmakers don't have to put their manufacturing in Ireland in order to shift profits out of the United States. Still. the strategy often involves putting it there. In recent months, as Mr. Trump threatened to impose punishing tariffs on medicines, most of the largest drugmakers announced plans to spend billions of dollars building or expanding U.S. factories. This spring, while under the threat of tariffs, the American drugmaker Merck announced a change for its cancer medication Keytruda — the best-selling drug on the planet — which it produces mainly in Ireland. Next year, the company plans to begin shifting Keytruda production for American patients to the United States. In the meantime, Merck and others have scrambled to transport medicines while they could still flow freely. In the first five months of this year, shipments of pharma products from Ireland to the United States were up nearly fourfold compared with the same period in 2024. Merck said it had shuttled enough Keytruda to the United States to supply American patients for the rest of the year. Irish trade data shows that about $35 billion worth of ingredients used in weight-loss drugs were exported out of Ireland in the first three months of this year. The bulk of those shipments were from Eli Lilly, which manufactures active ingredients for its popular obesity drug Zepbound in Ireland. Unlike India and China, where local companies manufacture low-cost generics, Ireland is where the world's biggest drugmakers produce expensive brand-name medicines. In County Cork, an industry hotbed in southwestern Ireland, Johnson & Johnson manufactures active ingredients for Darzalex, a cancer medication, and Stelara, which treats conditions like arthritis. At a facility a few hours north, in County Mayo, AbbVie formulates Botox. Last year, Ireland sent $50 billion worth of pharma products to the United States, most of which were made and shipped by multinational drug companies. This relationship has provoked the ire of the Trump administration. The president complained in March that Ireland's tax policies 'took our pharmaceutical companies away.' He added, 'This beautiful island of five million people has got the entire U.S. pharmaceutical industry in its grasp.' Howard Lutnick, the commerce secretary, said in an interview the same month that Ireland was running a 'tax scam' that American tech and pharma companies were exploiting. Tax experts and pharmaceutical executives have said that tariffs would be at best a blunt instrument for discouraging corporate activity in Ireland. Changing U.S. tax rules could more directly address the incentives that are motivating drugmakers, they said. Lower tax rates overseas 'drove a lot of the innovative companies to make drugs in low-tax islands like Ireland and Singapore and Switzerland,' said David Ricks, chief executive of Eli Lilly. He called for lower tax rates for companies making products in the United States. It remains to be seen whether tariffs and new U.S. factories will spur drugmakers to book more profits — and pay more taxes — in the United States. Where a company holds its intellectual property is more important for its tax bill than the location of its manufacturing, tax experts said. Nearly all of the largest pharma companies have a manufacturing presence in Ireland, in some cases dating back decades. The Irish government attracted drug companies by rewarding them for building factories and hiring local workers. The companies got not only tax advantages but also a skilled, English-speaking work force and easy access to the European market. Ireland, in turn, gained high-paying jobs, new factories and billions of euros in taxes that helped create an enormous budget surplus. Today, a vast majority of Ireland's corporate tax revenue comes from multinational drug companies and tech giants, which have also used Ireland to shift profits. Many large American drugmakers have complex webs of subsidiaries around the world, including in Ireland. In a typical arrangement, the Irish subsidiary and its parent company enter into a licensing deal: The subsidiary gets to exploit a drug's intellectual property, for instance by funding research. The subsidiary pays the parent company royalties but keeps most of the profits — often billions of dollars a year. This arrangement has allowed pharmaceutical companies to move profits out of Ireland and book them in tax havens like Bermuda or the Cayman Islands, which impose no income taxes at all, and where companies have no actual business activity. Over the past decade, global tax authorities have increasingly cracked down on such tactics. It is not clear how much the practices have abated. Irish officials said their country should not be dismissed as a tax shelter, pointing to the tens of thousands of Irish workers employed by multinational pharma companies. 'If it was a tax scam, then those people wouldn't be working,' said Daniel Mulhall, a former Irish ambassador to the United States. There was some sense of relief in Ireland that the 15 percent tariff was not higher, said Neil McGowan, an organizer for an Irish union that represents thousands of pharmaceutical workers. 'It's not a good situation to be in,' he said. 'But it could have been a lot worse.' In the longer term, he said, 'there are still concerns about what it's going to mean for people working in the industry here.' Drugmakers are expected to keep at least some of their manufacturing in Ireland regardless of the tariffs. But European Union officials, worried about the bloc's No. 1 export to the United States, fear that drugmakers will cut jobs or cancel or scale back planned expansions. For Keytruda, which is given as an intravenous infusion, a Merck factory in the Dublin suburb Swords makes the active ingredients. An hour away in Carlow, another Merck plant handles the next step of formulating the drug, according to the supply chain analytics firm QYOBO. Johanna Herrmann, a spokeswoman for the company, said no job cuts were being planned at Merck's Irish plants, which will continue to make Keytruda for countries other than the United States, along with other drugs. Merck recently broke ground on a factory in Delaware that is expected to begin making Keytruda in 2030. Until then, the company says, U.S. contract manufacturers will handle production for American patients. Plans to shift more of Merck's production to the United States were underway long before talk of tariffs, Ms. Herrmann said. Merck has been reaping tax benefits from producing Keytruda in Ireland. But Keytruda somewhat deviates from the typical industry playbook, in which American companies move their intellectual property overseas so they can shift their profits. Ms. Herrmann said that the patents protecting Keytruda have always been held in the Netherlands, where the drug was discovered in the 2000s before Merck acquired it. As a result, while three-fifths of Keytruda sales have been in the United States, Merck has booked much of the profits in the Netherlands. Susan C. Beachy contributed research.
